PL3277272T3 - Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego - Google Patents

Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego

Info

Publication number
PL3277272T3
PL3277272T3 PL16774191T PL16774191T PL3277272T3 PL 3277272 T3 PL3277272 T3 PL 3277272T3 PL 16774191 T PL16774191 T PL 16774191T PL 16774191 T PL16774191 T PL 16774191T PL 3277272 T3 PL3277272 T3 PL 3277272T3
Authority
PL
Poland
Prior art keywords
stratification
patients
treatment
methods
receptor agonists
Prior art date
Application number
PL16774191T
Other languages
English (en)
Inventor
Mei Wei CHEN
Cindy COLLINS
Matthew Lucas EATON
Matthew G. Guenther
Nan KE
Jeremy LOPEZ
Michael R. Mckeown
David A. Orlando
Original Assignee
Syros Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals, Inc. filed Critical Syros Pharmaceuticals, Inc.
Publication of PL3277272T3 publication Critical patent/PL3277272T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16774191T 2015-03-31 2016-03-31 Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego PL3277272T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562140999P 2015-03-31 2015-03-31
US201562268203P 2015-12-16 2015-12-16
PCT/US2016/025256 WO2016161107A1 (en) 2015-03-31 2016-03-31 METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS
EP16774191.7A EP3277272B1 (en) 2015-03-31 2016-03-31 Methods of stratifying patients for treatment with retinoic acid receptor-agonists

Publications (1)

Publication Number Publication Date
PL3277272T3 true PL3277272T3 (pl) 2022-01-24

Family

ID=57006493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16774191T PL3277272T3 (pl) 2015-03-31 2016-03-31 Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego

Country Status (14)

Country Link
US (5) US9845508B2 (pl)
EP (2) EP3967305A1 (pl)
JP (4) JP6952604B2 (pl)
KR (1) KR20170132248A (pl)
CN (2) CN116059365A (pl)
AU (3) AU2016243702B2 (pl)
BR (3) BR122023024814A2 (pl)
CA (1) CA2981518C (pl)
ES (1) ES2901792T3 (pl)
HU (1) HUE057325T2 (pl)
IL (3) IL309066A (pl)
MX (2) MX391949B (pl)
PL (1) PL3277272T3 (pl)
WO (1) WO2016161107A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906800A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing the effects of aging
IL309066A (en) 2015-03-31 2024-02-01 Syros Pharmaceuticals Inc Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
IL262156B2 (en) * 2016-04-08 2024-03-01 Syros Pharmaceuticals Inc Rara agonists for the treatment of aml and mds
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
WO2018136961A1 (en) * 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
JP2019043865A (ja) * 2017-08-31 2019-03-22 ひまわり製薬株式会社 ざ瘡様疾患を治療又は予防するための皮膚外用組成物
WO2020069187A1 (en) * 2018-09-28 2020-04-02 The Children's Medical Center Corporation Combination therapy for acute myeloid leukemia
BR112023002004A2 (pt) * 2020-08-06 2023-04-04 Syros Pharmaceuticals Inc Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170105B1 (en) 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2752630B2 (ja) 1988-03-29 1998-05-18 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
AU1666192A (en) 1991-03-22 1992-10-21 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
US5759785A (en) 1992-05-14 1998-06-02 Baylor College Of Medicine Method of identifying hormone antagonists and agonists
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR100485642B1 (ko) 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
DE69739909D1 (de) 1996-03-26 2010-07-29 Michael S Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999020309A1 (en) 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
WO2003025171A2 (en) * 2001-09-17 2003-03-27 Angiogene Inc. Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
EP2404596A1 (en) 2006-03-23 2012-01-11 TMRC Co., Ltd. Kit for Cancer Treatment and Pharmaceutical Composition for Cancer Treatment
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
MX2009009997A (es) 2007-03-30 2009-12-08 Tmrc Co Ltd Preparacion de la capsula de tamibarotene.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20100099084A1 (en) 2008-10-17 2010-04-22 Maher Albitar Detection of npm1 nucleic acid in acellular body fluids
US20130165520A1 (en) * 2010-02-11 2013-06-27 University De Montreal Hybrid Molecule Having Mixed Retinoic Acid Receptor Agonism and Histone Deacetylase Inhibitory Properties
US11116738B2 (en) * 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
WO2014066848A1 (en) 2012-10-25 2014-05-01 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
US20140296218A1 (en) 2012-10-25 2014-10-02 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
WO2014150300A2 (en) 2013-03-15 2014-09-25 Abbott Molecular Inc. Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
SG11201600293RA (en) 2013-07-15 2016-02-26 Univ Leland Stanford Junior Medical uses of cd38 agonists
EA201691144A1 (ru) 2013-12-06 2016-11-30 Селджин Корпорейшн Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
EP3089743B1 (en) 2013-12-30 2018-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
EP3267969A1 (en) 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
IL309066A (en) 2015-03-31 2024-02-01 Syros Pharmaceuticals Inc Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
IL262156B2 (en) 2016-04-08 2024-03-01 Syros Pharmaceuticals Inc Rara agonists for the treatment of aml and mds
WO2018067946A1 (en) 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY

Also Published As

Publication number Publication date
EP3277272A4 (en) 2018-09-26
IL294449B1 (en) 2024-01-01
EP3277272B1 (en) 2021-08-04
ES2901792T3 (es) 2022-03-23
US11447831B2 (en) 2022-09-20
IL309066A (en) 2024-02-01
US20180087115A1 (en) 2018-03-29
BR122023024814A2 (pt) 2024-02-20
HUE057325T2 (hu) 2022-04-28
IL254697B (en) 2022-08-01
RU2017134582A (ru) 2019-04-04
IL294449B2 (en) 2024-05-01
US20200392583A1 (en) 2020-12-17
BR112017020745A2 (en) 2018-07-17
US10697025B2 (en) 2020-06-30
JP2018514517A (ja) 2018-06-07
CN107613969A (zh) 2018-01-19
MX2022005020A (es) 2022-05-16
EP3967305A1 (en) 2022-03-16
KR20170132248A (ko) 2017-12-01
AU2022200059A1 (en) 2022-02-03
US20230042181A1 (en) 2023-02-09
JP2024081713A (ja) 2024-06-18
JP2020203911A (ja) 2020-12-24
AU2022200059B2 (en) 2024-05-23
CN116059365A (zh) 2023-05-05
MX391949B (es) 2025-03-21
AU2016243702B2 (en) 2021-10-07
US20160355888A1 (en) 2016-12-08
IL294449A (en) 2022-09-01
EP3277272A1 (en) 2018-02-07
IL254697A0 (en) 2017-11-30
MX2017012470A (es) 2018-03-23
US10167518B2 (en) 2019-01-01
JP6952604B2 (ja) 2021-10-20
US20180187271A1 (en) 2018-07-05
US9845508B2 (en) 2017-12-19
BR122023024813A2 (pt) 2024-02-20
JP2022185101A (ja) 2022-12-13
AU2016243702A1 (en) 2017-10-26
WO2016161107A1 (en) 2016-10-06
CA2981518A1 (en) 2016-10-06
RU2017134582A3 (pl) 2019-12-13
CA2981518C (en) 2024-06-25
CN107613969B (zh) 2022-07-22
AU2024216311A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
IL292504B1 (en) -methods of preparing t cells for t cell therapy
IL282156A (en) Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
IL312426B2 (en) Methods for training patients for T-cell therapy
PL3277272T3 (pl) Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
IL254734B1 (en) Modified t cells and methods of making and using the same
IL258358A (en) Quantitative heart testing
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3355734T3 (pl) Urządzenie do wytwarzania środka wdychalnego
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL252087B (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
DK3368060T3 (da) Glugacon-receptor-agonister
EP3068783A4 (en) Methods of treating heart failure with agonists of hypocretin receptor 2
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
ES2808978T8 (es) Heteroarilamidas como inhibidores de la agregación de proteínas
LT3007726T (lt) Tautopatijos gydymo būdai
HUE046397T2 (hu) Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása
IL257355B (en) Selection of patients for combination therapy
DK3145530T3 (da) Trail receptor agonists for treatment of fibrotic diseases
HRP20181914T1 (hr) Liječenje intrahepatičnih kolestatskih bolesti
IL256127B (en) Use of benzimidazole history for nocturnal acid reflux
IL257764B (en) Methods for treatment of diseases
IL254825A0 (en) Methods of treatment with taselisib
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HUE062482T2 (hu) Lactobacillus reuteri- és citráttartalmú készítmény gyógyászati felhasználásra